Co-resistance to Isoniazid and Second-line Anti-tuberculosis Drugs in Isoniazid-resistant Tuberculosis at a Tertiary Care Hospital in Thailand

Overview

Journal Microbiol Spectr

Specialty Microbiology

Date 2024 Feb 7

PMID 38323824

Authors

Ajala Prommi

Kanphai Wongjarit

Suthidee Petsong

Ubonwan Somsukpiroh

Kiatichai Faksri

Kamon Kawkitinarong

Sunchai Payungporn

Suwatchareeporn Rotcheewaphan

Affiliations

Soon will be listed here.

Abstract

Importance: The prevalence of isoniazid-resistant tuberculosis (Hr-TB) is the highest among other types of drug-resistant tuberculosis. Currently, the World Health Organization (WHO) guidelines recommend the treatment of Hr-TB with rifampicin, ethambutol, pyrazinamide, and levofloxacin for 6 months. The susceptibility profiles of Hr-TB clinical isolates, especially when they are co-resistant to second-line drugs, are critical in the selection of the appropriate treatment regimen to prevent treatment failure. This study highlights the susceptibility profiles of the WHO-recommended treatment regimen in Hr-TB clinical isolates from a tertiary care hospital in Thailand and the concordance and importance of using the phenotypic drug susceptibility testing or genotypic drug susceptibility testing for accurate and comprehensive interpretation of results.

Citing Articles

Advancing against drug-resistant tuberculosis: an extensive review, novel strategies and patent landscape.

Patel M, Patel A, Nandpal M, Raval M, Patel R, Patel A Naunyn Schmiedebergs Arch Pharmacol. 2024; .

PMID: 39377922 DOI: 10.1007/s00210-024-03466-0.

References

Sawatpanich A, Petsong S, Tumwasorn S, Rotcheewaphan S . Diagnostic performance of the Anyplex MTB/NTM real-time PCR in detection of complex and nontuberculous mycobacteria from pulmonary and extrapulmonary specimens. Heliyon. 2022; 8(12):e11935. PMC: 9719018. DOI: 10.1016/j.heliyon.2022.e11935. View

Bolger A, Lohse M, Usadel B . Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics. 2014; 30(15):2114-20. PMC: 4103590. DOI: 10.1093/bioinformatics/btu170. View

Shea J, Halse T, Kohlerschmidt D, Lapierre P, Modestil H, Kearns C . Low-Level Rifampin Resistance and Mutations in Mycobacterium tuberculosis: an Analysis of Whole-Genome Sequencing and Drug Susceptibility Test Data in New York. J Clin Microbiol. 2020; 59(4). PMC: 8579749. DOI: 10.1128/JCM.01885-20. View

Unissa A, Subbian S, Hanna L, Selvakumar N . Overview on mechanisms of isoniazid action and resistance in Mycobacterium tuberculosis. Infect Genet Evol. 2016; 45:474-492. DOI: 10.1016/j.meegid.2016.09.004. View

Morlock G, Tyrrell F, Baynham D, Escuyer V, Green N, Kim Y . Using Reduced Inoculum Densities of in MGIT Pyrazinamide Susceptibility Testing to Prevent False-Resistant Results and Improve Accuracy: A Multicenter Evaluation. Tuberc Res Treat. 2017; 2017:3748163. PMC: 5698819. DOI: 10.1155/2017/3748163. View

Riviere E, Whitfield M, Nelen J, Heupink T, Van Rie A . Identifying isoniazid resistance markers to guide inclusion of high-dose isoniazid in tuberculosis treatment regimens. Clin Microbiol Infect. 2020; 26(10):1332-1337. DOI: 10.1016/j.cmi.2020.07.004. View

Gygli S, Keller P, Ballif M, Blochliger N, Homke R, Reinhard M . Whole-Genome Sequencing for Drug Resistance Profile Prediction in . Antimicrob Agents Chemother. 2019; 63(4). PMC: 6496161. DOI: 10.1128/AAC.02175-18. View

Parks D, Imelfort M, Skennerton C, Hugenholtz P, Tyson G . CheckM: assessing the quality of microbial genomes recovered from isolates, single cells, and metagenomes. Genome Res. 2015; 25(7):1043-55. PMC: 4484387. DOI: 10.1101/gr.186072.114. View

Phelan J, OSullivan D, Machado D, Ramos J, Oppong Y, Campino S . Integrating informatics tools and portable sequencing technology for rapid detection of resistance to anti-tuberculous drugs. Genome Med. 2019; 11(1):41. PMC: 6591855. DOI: 10.1186/s13073-019-0650-x. View

10.

Puyen Z, Santos-Lazaro D, Vigo A, Coronel J, Alarcon M, Cotrina V . Evaluation of the broth microdilution plate methodology for susceptibility testing of Mycobacterium tuberculosis in Peru. BMC Infect Dis. 2022; 22(1):705. PMC: 9399989. DOI: 10.1186/s12879-022-07677-9. View

11.

. Epidemiological cut-off values for a 96-well broth microdilution plate for high-throughput research antibiotic susceptibility testing of . Eur Respir J. 2022; 60(4). PMC: 9556810. DOI: 10.1183/13993003.00239-2022. View

12.

Mok S, Roycroft E, Flanagan P, Montgomery L, Borroni E, Rogers T . Overcoming the Challenges of Pyrazinamide Susceptibility Testing in Clinical Mycobacterium tuberculosis Isolates. Antimicrob Agents Chemother. 2021; 65(8):e0261720. PMC: 8284449. DOI: 10.1128/AAC.02617-20. View

13.

Larsen M, Biermann K, Tandberg S, Hsu T, Jacobs Jr W . Genetic Manipulation of Mycobacterium tuberculosis. Curr Protoc Microbiol. 2008; Chapter 10:Unit 10A.2. DOI: 10.1002/9780471729259.mc10a02s6. View

14.

Banu S, Rahman S, Khan M, Ferdous S, Ahmed S, Gratz J . Discordance across several methods for drug susceptibility testing of drug-resistant Mycobacterium tuberculosis isolates in a single laboratory. J Clin Microbiol. 2013; 52(1):156-63. PMC: 3911413. DOI: 10.1128/JCM.02378-13. View

15.

Chien J, Chiu W, Chien S, Chiang C, Yu C, Hsueh P . Mutations in gyrA and gyrB among Fluoroquinolone- and Multidrug-Resistant Mycobacterium tuberculosis Isolates. Antimicrob Agents Chemother. 2016; 60(4):2090-6. PMC: 4808166. DOI: 10.1128/AAC.01049-15. View

16.

Metcalfe J, Streicher E, Theron G, Colman R, Penaloza R, Allender C . Mycobacterium tuberculosis Subculture Results in Loss of Potentially Clinically Relevant Heteroresistance. Antimicrob Agents Chemother. 2017; 61(11). PMC: 5655066. DOI: 10.1128/AAC.00888-17. View

17.

Nonghanphithak D, Chaiprasert A, Smithtikarn S, Kamolwat P, Pungrassami P, Chongsuvivatwong V . Clusters of Drug-Resistant Mycobacterium tuberculosis Detected by Whole-Genome Sequence Analysis of Nationwide Sample, Thailand, 2014-2017. Emerg Infect Dis. 2021; 27(3):813-822. PMC: 7920678. DOI: 10.3201/eid2703.204364. View

18.

Kamolwat P, Nateniyom S, Chaiprasert A, Disratthakit A, Mahasirimongkol S, Yamada N . Prevalence and associated risk factors of drug-resistant tuberculosis in Thailand: results from the fifth national anti-tuberculosis drug resistance survey. Trop Med Int Health. 2020; 26(1):45-53. DOI: 10.1111/tmi.13502. View

19.

Bankevich A, Nurk S, Antipov D, Gurevich A, Dvorkin M, Kulikov A . SPAdes: a new genome assembly algorithm and its applications to single-cell sequencing. J Comput Biol. 2012; 19(5):455-77. PMC: 3342519. DOI: 10.1089/cmb.2012.0021. View

20.

Dean A, Zignol M, Cabibbe A, Falzon D, Glaziou P, Cirillo D . Prevalence and genetic profiles of isoniazid resistance in tuberculosis patients: A multicountry analysis of cross-sectional data. PLoS Med. 2020; 17(1):e1003008. PMC: 6974034. DOI: 10.1371/journal.pmed.1003008. View